Not available
Quote | Theravance Biopharma Inc. (NASDAQ:TBPH)
Last: | $10.21 |
---|---|
Change Percent: | 0.3% |
Open: | $9.97 |
Close: | $10.21 |
High: | $10.2663 |
Low: | $9.89 |
Volume: | 270,400 |
Last Trade Date Time: | 07/25/2024 03:00:00 am |
News | Theravance Biopharma Inc. (NASDAQ:TBPH)
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 PR Newswire DUBLIN , July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update...
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | Theravance Biopharma Inc. (NASDAQ:TBPH)
Subject | By | Source | When |
---|---|---|---|
On the move back up. Smart money | ok2buy | investorshub | 09/02/2021 2:42:13 PM |
May have bought a little too early, but | ok2buy | investorshub | 08/28/2021 1:47:56 PM |
Put my money where my mouth is, filled | ok2buy | investorshub | 08/24/2021 3:26:24 PM |
Missed their end point in the Phase IIB | ok2buy | investorshub | 08/24/2021 2:52:42 PM |
whytestocks: $TBPH bears and bulls | whytestocks | investorshangout | 11/17/2019 2:25:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 PR Newswire DUBLIN , July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update...
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...